2021
Infectious Complications Predict Premature CD8+ T-cell Senescence in CD40 Ligand-Deficient Patients
Shin JJ, Catanzaro J, Yonkof JR, Delmonte O, Sacco K, Shin MS, Reddy S, Whittington PJ, Soffer G, Mustillo PJ, Sullivan KE, Notarangelo LD, Abraham RS, Romberg N, Kang I. Infectious Complications Predict Premature CD8+ T-cell Senescence in CD40 Ligand-Deficient Patients. Journal Of Clinical Immunology 2021, 41: 795-806. PMID: 33495902, PMCID: PMC8329305, DOI: 10.1007/s10875-021-00968-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge of OnsetBiomarkersCase-Control StudiesCD40 LigandCD8-Positive T-LymphocytesCellular SenescenceChild, PreschoolGenes, X-LinkedGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmune System DiseasesImmunophenotypingInfectionsPedigreePhenotypePrognosisReceptors, Antigen, T-CellYoung AdultConceptsT cell senescenceCD40L-deficient patientsImmunoglobulin G replacementHealthy controlsT cellsInfectious complicationsCD40L deficiencyT-cell receptor excision circle analysisPneumocystis jirovecii pneumonia prophylaxisCMV-specific proliferationPatient group 2Effector memory CD8Effective prophylactic strategyCytokine release assaysAdult healthy controlsEarly CD8Pneumonia prophylaxisProphylaxis adherenceResultsThree patientsProphylactic antibioticsSenescence-associated moleculesMemory CD8Childhood pneumoniaInfectious exposureRecurrent infections
2020
Community Private Practice Clinical Experience with Peanut Oral Immunotherapy
Afinogenova Y, Rubin T, Patel S, Powell R, Gilo J, Denno M, Soffer G, Lee J, Mendelson L, Factor J. Community Private Practice Clinical Experience with Peanut Oral Immunotherapy. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2727-2735. PMID: 32247684, DOI: 10.1016/j.jaip.2020.03.016.Peer-Reviewed Original ResearchConceptsPeanut oral immunotherapyPeanut-specific IgE levelsCutaneous adverse eventsRespiratory adverse eventsGastrointestinal adverse eventsAdverse eventsSpecific IgE levelsPeanut-allergic patientsOral immunotherapySystemic reactionsIgE levelsAdverse reactionsRetrospective chart reviewSpecific patient characteristicsMaintenance phaseAllergic profileGastrointestinal symptomsChart reviewImmunologic factorsPatient characteristicsPatient demographicsBlood pressureEosinophilic esophagitisAllergy testingPeanut allergy
2017
Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of late‐onset primary isolated central nervous system hemophagocytic lymphohistiocytosis
Khazal S, Polishchuk V, Soffer G, Prinzing S, Gill J, Mahadeo KM. Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of late‐onset primary isolated central nervous system hemophagocytic lymphohistiocytosis. Pediatric Transplantation 2017, 22 PMID: 29239076, DOI: 10.1111/petr.13101.Peer-Reviewed Original ResearchConceptsCNS-HLHDurable remissionsReduced-intensity conditioning regimenHematopoietic stem cell transplantationActive CNS diseaseLate-onset primaryStem cell transplantationAllogeneic HSCTCNS presentationsComorbidity indexConditioning regimenDisease remissionPrompt treatmentHemophagocytic lymphohistiocytosisSignificant morbidityPoor outcomeCell transplantationCNS diseaseAdolescent patientsPRF1 mutationsEarly diagnosisHigh indexRare diseaseRemissionImproved cure